Compare Abbott Laboratories (ABT) vs Starbucks Corp (SBUX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Starbucks Corp — how do they compare? Abbott Laboratories trades at $95.37 (market cap $166.94B), while Starbucks Corp trades at $103.07 (market cap $118.08B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | SBUX | |
|---|---|---|
Market Cap | $166.94B | $118.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $106.82 |
52-Week Low | $82.57 | $78.46 |
Enterprise Value | $193.69B | $140.78B |
Dividend Yield | 2.63% | 2.39% |
Volume | — | 7,493,833 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Starbucks (SBUX) trades at $103.61, down 0.62% with a bullish technical signal despite recent price weakness. The company shows mixed fundamentals with declining net income margins (3.89% in 2025) but stable revenue growth. Recent earnings beat expectations in Q1 2026 after two consecutive misses. Analyst consensus remains positive with a $107.67 price target, though technical indicators show neutral oscillators and key resistance at $104.
SBUX faces margin pressure but benefits from strong brand loyalty and store traffic initiatives. Investment opportunity lies in international expansion and operational improvements, while risks include competitive pressures and cost inflation. The stock offers moderate upside potential with balanced analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
